Yale Study Identifies Effective Interventions to Slow Aging Process
A recent analysis conducted by researchers at Yale University has provided insights into interventions that may slow the aging process. The study, led by Raghav Sehgal, an associate research scientist in psychiatry, began with a broader question posed by his thesis adviser: if it is possible to solve age-related diseases like cancer and cardiovascular disease, why not tackle aging itself? This inquiry has led to significant findings regarding how certain lifestyle choices and medications can influence biological aging.
The researchers utilized advanced blood-based DNA tests to evaluate the effectiveness of various interventions. Their analysis revealed that prescribed medications for metabolic control and weight management, such as metformin and semaglutide, along with a combination of healthy diet and exercise, are among the most effective strategies for slowing biological aging. The study, published in the journal Nature Medicine, emphasizes the need for further research to validate these findings.
Sehgal's research focuses on understanding the biological systems that drive aging and measuring its effects. The study combined data from 51 anti-aging intervention studies, assessing over 110 DNA methyl biomarkers, which are indicators of biological age based on chemical changes in DNA. The researchers found that lifestyle interventions consistently decreased epigenetic age, while pharmacological interventions showed the most significant impact.
The analysis categorized interventions into four groups: pharmacological drugs, lifestyle changes, over-the-counter supplements, and medical procedures. Results indicated that lifestyle changes, particularly a balanced diet—whether Mediterranean, low-fat, or low-carb—combined with regular exercise, effectively reduced epigenetic age. In contrast, over-the-counter supplements and certain medical procedures did not demonstrate a significant effect on biological aging.
Sehgal noted that this research marks a pivotal moment in understanding how specific therapies can have measurable impacts on aging. The study's findings suggest that with the advancement of new biomarkers, researchers may be able to evaluate anti-aging therapies more efficiently, potentially shortening the timeline for understanding effective interventions. The next steps involve broader testing across diverse populations to further explore the efficacy of these interventions in slowing aging.




